Acute Leukaemia panel

General information

Panel of markers used: CD2, CD10, CD13, CD14, CD19, CD33, CD34, CD79a, CD117, Tdt, MPO

Specimen transport: At room temperature

Repeat frequency: Post treatment monitoring, suspected relapse and MRD

Special conditions/precautions: Do not refrigerate samples

Laboratory information

Reporting units: Percentage of the population of cells of interest

Volume and sample type: 5mls EDTA blood, bone marrow or fluid samples (e.g. ascitic fluid, bronchoalveolar lavage, CSF, EBUS, fine needle aspirates or pleural fluids)

Method: Flow cytometry

Turnaround time (calendar days from sample receipt to authorised result): Median – 2

Participation in EQA Scheme: UK NEQAS Leukaemia Immunophenotyping Part 1 and 2

Clinical information

Indications for the test: Suspected acute Leukaemia

Factors affecting the test: None

(Last updated June 2021)